← All indications
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
Subtype terms (20)
More specific conditions that are subtypes of Carcinoma in the MeSH hierarchy.
- Adenocarcinoma
227 drugs (120 approved, 107 experimental)
- Carcinoma, Adenosquamous
13 drugs (8 approved, 5 experimental)
- Carcinoma, Basosquamous
- Carcinoma, Ehrlich Tumor
- Carcinoma, Giant Cell
22 drugs (20 approved, 2 experimental)
- Carcinoma in Situ
22 drugs (16 approved, 6 experimental)
- Carcinoma, Krebs 2
- Carcinoma, Large Cell
11 drugs (9 approved, 2 experimental)
- Carcinoma, Lewis Lung
- Carcinoma, Ovarian Epithelial
172 drugs (65 approved, 107 experimental)
- Carcinoma, Papillary
- Carcinoma, Small Cell
52 drugs (27 approved, 25 experimental)
- Carcinoma, Squamous Cell
373 drugs (153 approved, 220 experimental)
- Carcinoma, Transitional Cell
423 drugs (136 approved, 287 experimental)
- Carcinoma, Verrucous
60 drugs (38 approved, 22 experimental)
- Mammary Analogue Secretory Carcinoma
- Nasopharyngeal Carcinoma
209 drugs (87 approved, 122 experimental)
- Non-Melanoma Skin Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
5 drugs (1 approved, 4 experimental)
- Thyroid Carcinoma, Anaplastic
35 drugs (20 approved, 15 experimental)
Drugs by status
Approved for this indication (15)
Phase 4 trials (13)
Phase 3 trials (55)
- cisplatin
- vincristine
- bevacizumab
- cemiplimab
- gefitinib
- nivolumab
- lanreotide
- sunitinib
- escitalopram
- ferric carboxymaltose
- tranexamic acid
- pralsetinib
- nimotuzumab
- capecitabine
- relatlimab
- porfiromycin
- nicotinamide
- pembrolizumab
- 11-valent recombinant human papilloma virus vaccine
- modotuximab
- aflibercept
- everolimus
- levoleucovorin
- volitinib
- docetaxel
- cyclophosphamide
- denosumab
- futuximab
- crizotinib
- leucovorin
- +25 more
Phase 2 trials (166)
- p16_37-63
- ixazomib
- syha1815
- hydroxychloroquine
- ino-3112
- vk-2019
- mogamulizumab
- ipilimumab
- vandetanib
- avelumab
- water
- vb10.16
- tarlatamab
- penpulimab
- anlotinib
- Nanatinostat
- trifluridine
- interleukin-12
- xnw5004
- tocilizumab
- camrelizumab
- tislelizumab
- enfortumab vedotin
- autogene cevumeran
- autologous hematopoietic stem cells
- dostarlimab
- isa-51
- trebananib
- Eganelisib
- ivocizumab
- +136 more
Phase 1 trials (100)
- ad-e6e7
- tsa-reactive tcr-engineered t cells
- fam-trastuzumab deruxtecan-nxki
- syn125
- fludeoxyglucose f-18
- 89zr-lncab190
- 4-1bbζ egfr806-egfrt
- ibrx-042
- enoblituzumab
- amt-151
- hs-10241
- tsc-204-a0201
- blu-667
- ketoconazole
- 4-1bbζ cd19-her2tg
- autologous natural killer cells
- luteolin
- hydroxyurea
- brentuximab vedotin
- temsirolimus
- p16_37-63 peptide
- montanide isa51
- cdx-1140
- 64cu-dota-u3-1287
- rifampin
- autologous muc1-activated t-cells
- mt-302
- ceramide
- neratinib maleate
- ezn-296
- +70 more
Organizations
Organization Involved with Phase 4 Indications (93)
- Kyoto University
- Fudan University
- I-Shou University
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Medical College of Wisconsin
- University of Michigan
- National Cancer Institute, France
- Université catholique de Louvain
- Celgene
- Taipei Medical University
- Kaohsiung Medical University
- China Medical University
- Badalona Hospital Germans Trias i Pujol
- Mario Negri Institute
- Eisai
- Bukwang Pharmaceutical
- University of Tuebingen
- Johnson and Johnson
- Peking University
- Ludwig Maximilians University
- University of Lyon
- Beijing Weida Cancer Hospital of Chinese Traditional Medical Sciences
- National Taiwan University
- National Cancer Institute (NCI)
- Soochow University
- Biotech Pharmaceutical Co., Ltd.
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
- University of Helsinki
- University of Electronic Science and Technology of China
- Wake Forest University
- +63 more
Organization Involved with Phase 3 Indications (408)
- NRG Oncology
- Australasian Gastro-Intestinal Trials Group
- TTY Biopharm
- Harbin Medical University
- Zhengzhou University
- Henry Ford Health System
- J. W. Goethe University
- Blokhin's Russian Cancer Research Center
- Sanofi
- Associazione Italiana per la Ricerca sul Cancro
- Shanxi Medical University
- Mayo Clinic
- Guangdong Pharmaceutical University
- Novelion Therapeutics
- University of South Florida
- Jiangnan University
- Optimal Health Research
- Sichuan University
- University Hospital Birmingham NHS Foundation Trust
- Universidad de Murcia
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Eastern Cooperative Oncology Group
- Shengjing Hospital
- University of Pisa
- First People's Hospital of Yulin
- Yonsei University
- Southern Medical University
- Tufts University
- Innovent Biologics (Suzhou) Co. Ltd.
- Government of Taiwan
- +378 more
Organization Involved with Phase 2 Indications (702)
- Pusan National University
- University of California, Irvine
- Saint Francis Memorial Hospital
- Ameriderm Research
- University of Salzburg
- Agensys, Inc.
- SRH Wald-Klinikum Gera GmbH
- Immutep S.A.
- Laval University
- University of Medicine and Dentistry of New Jersey
- Hestia Duran i Reynals
- Vyriad, Inc.
- Regional Cancer Centre, Trivandram
- University of Grenoble
- ClinAssess GmbH
- Ontario Institute for Cancer Research
- Leap Therapeutics, Inc.
- University of Southern California
- University of Sydney
- HealthCare Global Enterprise Ltd.
- Mansoura University
- ValiRx
- Ospedaliera Valtellina
- Korean South West Oncology Group
- Shandong New Time Pharmaceutical Co., LTD
- National Comprehensive Cancer Network
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Gyeongsang University
- Grupo Espanol Multidisciplinario del Cancer Digestivo
- CbsBioscience
- +672 more
Organization Involved with Phase 1 Indications (180)
- Florida Department of Health
- Jagiellonian University
- Bnai Zion Medical Center
- BioNumerik Pharmaceuticals, Inc.
- GenVivo, Inc.
- Insys Therapeutics Inc
- Fiverings Co., Ltd.
- BioClever 2005 S.L.
- Provectus Biopharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Lotte & John Hecht Memorial Foundation
- Intrexon
- Likang Life Sciences
- TKL Research
- Lytix Biopharma AS
- Morphogenesis, Inc.
- Eastern Virginia Medical School
- Cancer Care Northwest
- Stand Up To Cancer
- SkinJect, Inc.
- University of Geneva
- Shin Kong Wu Ho-Su Memorial Hospital
- ICON
- Lakeland Regional Medical Center
- INRASTES, NCSR Demokritos, Athens, Greece
- Barretos Cancer Hospital
- Cantargia AB
- Shattuck Labs
- Galera Therapeutics
- Surface Oncology
- +150 more
Organization Involved with Other Experimental Indications (39)
- Centre Jean Perrin
- University of Stavanger
- Charles Drew University
- Vietnamese Military
- Melbourne Health
- Howard Hughes Medical Institute
- Federal University of Health Science of Porto Alegre
- Naestved Hospital
- Norwegian University of Science and Technology
- NuBiyota
- Western Infirmary
- Institute of Liver and Biliary Sciences, India
- Government of Mexico
- Verbeeten Insituut Tilburg
- Government of Hong Kong
- Kyung Hee University
- Noordwest Ziekenhuisgroep
- DUSA Pharmaceuticals
- Galderma
- Rouen Normandy University
- Hudlegekontoret Lillehammer
- Boston Scientific Corporation
- Deventer Ziekenhuis
- Zuyderland Medisch Centrum
- Shiyan Taihe Hospital
- Isala Clinics, Zwolle, The Netherlands
- Rijnstate Hospital
- Pavlov First Saint Petersburg State Medical University
- Sprint for Life
- Institute of hepatobiliary surgery,Southwest Hospital
- +9 more